Cancer clinical trials in the region Île-de-France

726 currently recruiting clinical trials
Region Île-de-France
Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT04116541 #2023-510567-35-00
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
BRAF
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
8 recruiting sites
Centre Léon Bérard
Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT04116541 #2023-510567-35-00
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
ALK
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
8 recruiting sites
Centre Léon Bérard
Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT04116541 #2023-510567-35-00
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
Other mutation
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
8 recruiting sites
Centre Léon Bérard
Phase 2 Lung cancer #NCT07288177 #2025-522107-18-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Non-squamous NSCLC
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
3 recruiting sites
Genmab
Phase 2 Chronic myeloid leukemia (CML) #NCT02889003
Required number of previous lines of therapy
1
Required previous treatments
ATP pocket inhibitor Allosteric inhibitor
Excluded genetic anomalies
BCR-ABL
Excluded previous treatments
Systemic Treatment-Naive Allogeneic stem cell transplant
3 recruiting sites
Hôpital de Versailles
Phase 2 Acute leukemia #NCT07007052 #2024-511003-42-00
Required histologic types
Blastic plasmacytoid dendritic cell neoplasm (BPDC...
Required renal function statuses
> 60 ml/min
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
8 recruiting sites
French Innovative Leukemia Organisation (FILO)
Phase 2 Lymphoma #NCT05139017 #2022-502646-27-00
Required histologic types
B cell lymphoma
Required histologic sub types
Large B cell lymphoma
Required central nervous system lesions
None Treated / Controled
Required number of previous lines of therapy
1 2 3 or more
Required previous treatments
Car-T Autologous stem cell transplant
Excluded previous treatments
Systemic Treatment-Naive
2 recruiting sites
Merck Sharp & Dohme LLC
Phase 2 Lymphoma #NCT04984837 #2024-513252-15-00
Required histologic types
T cell lymphoma
Required histologic sub types
Peripheral T cell lymphoma
Required central nervous system lesions
None
Required renal function statuses
> 60 ml/min 50-60 ml/min 30-50 ml/min
Required number of previous lines of therapy
1 2
Required previous treatments
Chemotherapy
Excluded previous treatments
Systemic Treatment-Naive Allogeneic stem cell transplant
1 recruiting site
The Lymphoma Academic Research Organisation (LYSARC)
Phase 2 Lung cancer #NCT07098338 #2025-524843-11-00
Sous étude 1 et 2
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced Metastatic
Required PDL1 statuses
PDL1 Negative (< 1%) PDL1 Positive (1% <= X < 25%) PDL1 Positive (25% <= X < 50%) PDL1 Positive (>= 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK EGFR
Excluded previous treatments at advanced or metastatic stage
Immunotherapy Chemotherapy Radiotherapy
1 recruiting site
AstraZeneca
Phase 2 Lung cancer #NCT07098338 #2025-524843-11-00
Sous-étude 3
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Non-squamous NSCLC
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2
Required previous treatments at advanced or metastatic stage
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
AstraZeneca